[1]Arroyo V, Ginès P, Gerbes AL, et al.Definition and diagnosticcriteria of refractory ascites and hepatorenal syndrome in cirrhosis.International Ascites Club[J].Hepatology, 1996, 23 (1) :164-176.
|
[2]Salerno F, Gerbes A, Gines P, et al.Diagnosis, prevention andtreatment of hepatorenal syndrome in cirrhosis[J].Gut, 2007, 56 (9) :1310-1318.
|
[3]Runyon BA.Management of adult patients with ascites due to cirrho-sis:an update[J].Hepatology, 2009, 49 (6) :2087-2107.
|
[4]European Association for the Study of the Liver.EASL clinical prac-tice guidelines on the management of ascites, spontaneous bacterialperitonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.
|
[5]Sanyal AJ, Boyer T, Garcia-Tsao G, et al.A randomized, pro-spective, double-blind, placebo-controlled trial of terlipressin fortype 1 hepatorenal syndrome[J].Gastroenterology, 2008, 134 (5) :1360-1368.
|
[6]Martín-LlahíM, Pépin MN, Guevara M, et al.Terlipressin and al-bumin vs albumin in patients with cirrhosis and hepatorenal syn-drome:a randomized study[J].Gastroenterology, 2008, 134 (5) :1352-1359.
|
[7]中华医学会.肝衰竭诊疗指南[J].中华肝脏病杂志, 2006, 14 (9) :643-646.
|
[8]Alessandria C, Venon WD, Marzano A, et al.Renal failure in cir-rhotic patients:role of terlipressin in clinical approach to hepatorenalsyndrome type 2[J].Eur J Gastroenterol Hepatol, 2002, 14 (12) :1363-1368.
|
[9]Duvoux C, Zanditenas D, Hézode C, et al.Effects of noradrenalinand albumin in patients with type I hepatorenal syndrome:a pilotstudy[J].Hepatology, 2002, 36 (2) :374-380.
|
[10]Sharma P, Kumar A, Shrama BC, et al.An open label, pilot, ran-domized controlled trial of noradrenaline versus terlipressin in thetreatment of type 1 hepatorenal syndrome and predictors of response[J].Am J Gastroenterol, 2008, 103 (7) :1689-1697.
|
[11]Skagen C, Einstein M, Lucey MR, et al.Combination treatment withoctreotide, midodrine, and albumin improves survival in patients withtype 1 and type 2 hepatorenal syndrome[J].J Clin Gastroenterol, 2009, 43 (7) :680-685.
|
[12]Nazar A, Pereira GH, Guevara M, et al.Predictors of response totherapy with terlipressin and albumin in patients with cirrhosis andtype 1 hepatorenal syndrome[J].Hepatology, 2010, 51 (1) :219-226.
|
[1] | XU Zhen, LIU ShouSheng, TAN Jie, SUN BaoKai, DU ShuiXian, XIN YongNing, XUAN ShiYing. Expression and significance of leptin and adiponectin in serum of patients with nonalcoholic fatty liver disease and coronary heart disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2478-2483. doi: 10.3969/j.issn.1001-5256.2020.11.016 |
[2] | Wang CuiHua, Yue Yan. Research progress in relationship of leptin and adiponectin with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(8): 1351-1354. doi: 10.3969/j.issn.1001-5256.2015.08.045 |
[3] | Kong Yin, Zhang LingYi. The role of leptin and adiponectin in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(4): 441-443. |
[4] | Zhao ZhengBin, Li JunFeng, Huang ShuangSheng, Zhang LiTing, Chen Hong. The advances of profibrogenic research of leptin and its signaling pathways in hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1106-1108. |
[6] | Wang ChunPing, Zhang Ming. Evaluation of leptin receptor Gln223Arg polymorphism in patients with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2008, 24(3): 194-196. |
[7] | Li Mei, Liang YingYin, Lin HongZheng, Xu Ya, Chen SongLin, Liu SiChun. Clinical analysis of 32 cases with alcoholic liver disease and alcohol with drawal syndrome[J]. Journal of Clinical Hepatology, 2007, 23(1): 38-39. |
[8] | Li YuQin, Po YunFeng, Chen ZhaoJie, Ding BaiJing, Tang TongYu, Wang Dan, Gao YanHang, Jin JingLan. Relationship between the levels of serum leptin and insulin resistance in patients with fatty liver[J]. Journal of Clinical Hepatology, 2007, 23(5): 360-361. |
[9] | Li RuiYan, Xiong JinHu. Evaluation of the clinical value of the concentration of leptin in viral hepatitis[J]. Journal of Clinical Hepatology, 2007, 23(2): 96-97. |
[11] | Liu FengHai, Sun LinYu, Tan HaiYan, Liu XiaoLi. The clinical significance of serum leptin levels in patients with nonalcoholic fatty liver[J]. Journal of Clinical Hepatology, 2006, 22(1): 41-42. |
[12] | Zheng JiMin, Jiang HuiQing, Lu: XiaoPing, Zhang XiangMei. Measurement of ghrelin leptin levels in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2006, 22(3): 195-196. |
[13] | Lu ZhenYa, Wang QunYan, Rao WeiQiang, Cai WeiMin. Relationship between leptin resistance and nonalcoholic fatty liver in male patients.[J]. Journal of Clinical Hepatology, 2006, 22(1): 39-41. |
[14] | Wang RuiKe, Liu XiuZhen, Zhang GuYun, Li Hong, Sun ZhaoCui, Zhang JinAn. Monitoring the change of interleukin-6 in the alcoholic liver disease and its clinical significance[J]. Journal of Clinical Hepatology, 2005, 21(2): 100-101. |
[15] | Wang HaiQin, Li JuanJuan. Therapeutic effect of GSH on the treatment of alcoholic liver diseases.[J]. Journal of Clinical Hepatology, 2004, 20(6): 355-356. |
[16] | Li ChuanFeng, Huang YongCan, Qiu Xiang, Po YunFeng. Clinical analysis of 146 cases of alcoholic liver diseases.[J]. Journal of Clinical Hepatology, 2004, 20(3): 157-158. |
[17] | Lu ZhenYa, Wang QunYan, Rao WeiQiang, Cai WeiMin, Liu RongHua. The relationship between serum leptin levels and the levels of fibrosis marks in patients with hepatitis B.[J]. Journal of Clinical Hepatology, 2004, 20(2): 85-86. |